Synaptic

Adonis's Revenue Surges 9x, Capping Milestone Year for Innovative Revenue Cycle Technology Company

Retrieved on: 
Wednesday, December 20, 2023

NEW YORK, Dec. 20, 2023 /PRNewswire/ -- Adonis, a leading Revenue Intelligence and Automation platform, announced today a year of meaningful revenue growth and significant company milestones. These include a substantial investment round, prominent features, partnership announcements, and the launching of two new products – all helping to further Adonis's mission to deliver critical revenue outcomes that enable healthcare providers to deliver the highest form of clinical outcomes and care.

Key Points: 
  • NEW YORK, Dec. 20, 2023 /PRNewswire/ -- Adonis, a leading Revenue Intelligence and Automation platform, announced today a year of meaningful revenue growth and significant company milestones.
  • "Our vision is to empower billing and revenue teams across healthcare with our cutting-edge products so they can recover the revenue they deserve – and this is only the beginning.
  • We believe a dynamic specialty specific AI-driven payment collection process is integral to building an agile and innovative company like Adonis."
  • "Adonis's success to date is not an accident: challenges in revenue cycle management are both universal and well documented.

Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD

Retrieved on: 
Tuesday, October 24, 2023

SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D., Ph.D., acting as principal investigator.

Key Points: 
  • SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D., Ph.D., acting as principal investigator.
  • The poster describing changes in brain wave patterns in adults with mild-to-moderate Alzheimer’s disease following 28-days of treatment with CT1812 or placebo will be on display through the conclusion of CTAD.
  • In the SEQUEL study , CT1812-treated participants exhibited a statistically significant change in relative theta in the central region of the brain and consistent trends of improvement across all prespecified EEG parameters.
  • “CT1812 treatment showed improvement of EEG parameters that are consistent in magnitude and effect size with previously reported trials,” explained Dr. de Haan.

Screenless Display Market to grow by USD 5.44 billion from 2022 to 2027 | Market driven by rising demand for more convenient and portable display solutions- Technavio

Retrieved on: 
Wednesday, October 4, 2023

The potential growth difference for the screenless display market between 2022 and 2027 is USD 5.44 billion.

Key Points: 
  • The potential growth difference for the screenless display market between 2022 and 2027 is USD 5.44 billion.
  • Rising demand for more convenient and portable display solutions notably drives the market growth.
  • These multifaceted drivers collectively contribute to an increasing demand for screenless displays, thereby propelling the growth of the screenless display market during the forecast period.
  • Key Companies in the screenless display market:
    The Location-Based Virtual Reality (VR) Market size is estimated to grow at a CAGR of 33.7% between 2022 and 2027.

SYNAPS Dx Observes September as World Alzheimer’s Month and Healthy Aging Month: Celebrates Researchers, Providers and Patients

Retrieved on: 
Tuesday, September 26, 2023

The 2023 theme ‘Never too early, never too late’ highlights the need for an early and accurate diagnosis of AD and the importance of recognizing AD risk factors.

Key Points: 
  • The 2023 theme ‘Never too early, never too late’ highlights the need for an early and accurate diagnosis of AD and the importance of recognizing AD risk factors.
  • Awareness of risk reduction strategies is crucial, especially for those who are not yet showing symptoms.
  • A minimally invasive, 3mm skin punch biopsy , DISCERN can be administered in a primary care setting.
  • DISCERN assesses factors closely related to the formation of synaptic connections in the brain as well as the formation of amyloid plaque and abnormal tau.

SYNAPS Dx DISCERN™ Test Provides Accurate Diagnosis of Alzheimer’s Disease, Optimizes Prescribing, Minimizes Patient Risks and Informs Coverage Decisions for Leqembi™

Retrieved on: 
Tuesday, July 11, 2023

Pursuant to the Leqembi label , once AD is identified, then an assessment of amyloid positivity can be performed in determining if the drug is appropriate.

Key Points: 
  • Pursuant to the Leqembi label , once AD is identified, then an assessment of amyloid positivity can be performed in determining if the drug is appropriate.
  • In clinical utility studies, clinicians were four times more likely to prescribe drugs like Leqembi with a positive DISCERN test than if the test was negative.
  • The established relationship between AD and the skin provides unique positioning for DISCERN which requires a minimally invasive, 3mm skin punch biopsy .
  • “AD is complex but DISCERN resolves the diagnostic dilemma , enabling physicians to make a more definitive diagnosis,” continues Amato.

SYNAPS Dx Honors Alzheimer’s & Brain Awareness Month: Highlights Value of DISCERN™ as Only Skin Test to Accurately Diagnose Alzheimer’s Disease

Retrieved on: 
Tuesday, June 6, 2023

The DISCERN™ diagnostic test assesses factors closely related to the formation of synaptic connections in the brain as well as the formation of amyloid plaque and abnormal tau.

Key Points: 
  • The DISCERN™ diagnostic test assesses factors closely related to the formation of synaptic connections in the brain as well as the formation of amyloid plaque and abnormal tau.
  • Synaptic connections are lost as cognitive functions decline, even early in AD.
  • Amyloid plaques and abnormal tau are the pathologic hallmarks in the brain at autopsy that, together with dementia, definitively identify those patients with AD.
  • “The established relationship between AD and the skin provides unique positioning for DISCERN which requires a minimally invasive, 3mm skin punch biopsy .

Memories may be stored in the membranes of your neurons

Retrieved on: 
Tuesday, May 9, 2023

Its information processing capabilities are what allow you to learn, and it is the central repository of your memories.

Key Points: 
  • Its information processing capabilities are what allow you to learn, and it is the central repository of your memories.
  • Research from our team of biophysicists, physical chemists and materials scientists suggests that memory might be located in the membranes of neurons.
  • The changes taking place between these two membranes, commonly known as synaptic plasticity, are the primary mechanism for learning and memory.
  • These include changes to the amounts of different proteins in the membranes, as well as the structure of the membranes themselves.

Automotive LCD Display Market Expected to Reach $12.2 Billion, Globally, By 2031 at 5.6% CAGR: Allied Market Research

Retrieved on: 
Thursday, December 1, 2022

PORTLAND, Ore., Dec. 1, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Automotive LCD Display Market By Display Size (Upto 7 inch, and More than 7 inch), Vehicle Type (Passenger Car, Light Commercial Vehicle, and Heavy Commercial Vehicle): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global automotive LCD display industry generated $7.2 billion in 2021, and is anticipated to generate $12.2 billion by 2031, witnessing a CAGR of 5.6% from 2022 to 2031.

Key Points: 
  • Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of " Market Research Reports " and "Business Intelligence Solutions."
  • AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
  • Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success.
  • Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Automotive LCD Display Market Expected to Reach $12.2 Billion, Globally, By 2031 at 5.6% CAGR: Allied Market Research

Retrieved on: 
Thursday, December 1, 2022

PORTLAND, Ore., Dec. 1, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Automotive LCD Display Market By Display Size (Upto 7 inch, and More than 7 inch), Vehicle Type (Passenger Car, Light Commercial Vehicle, and Heavy Commercial Vehicle): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global automotive LCD display industry generated $7.2 billion in 2021, and is anticipated to generate $12.2 billion by 2031, witnessing a CAGR of 5.6% from 2022 to 2031.

Key Points: 
  • Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of " Market Research Reports " and "Business Intelligence Solutions."
  • AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
  • Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success.
  • Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Enphase Energy Expands IQ8 Microinverter Deployments in Texas

Retrieved on: 
Tuesday, June 21, 2022

FREMONT, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, announced today that installers of Enphase products in Texas have seen growing deployments of Enphase Energy Systems powered by IQ8 Microinverters following the products launch in North America late last year.

Key Points: 
  • FREMONT, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, announced today that installers of Enphase products in Texas have seen growing deployments of Enphase Energy Systems powered by IQ8 Microinverters following the products launch in North America late last year.
  • With Enphase technology, Texans can achieve a new level of energy independence and security, said Stan Pipkin, CEO at Lighthouse Solar , an Enphase Gold level installer.
  • The Enphase Energy System uses sophisticated grid-forming microinverter and battery technology so that Texas homeowners can meet their Texas-sized energy needs by generating and using their own power from the sun.
  • The Enphase Energy System, featuring IQ8 Microinverters and IQ Batteries, gives customers a great experience and more energy independence.